INFECTIOUS EXACERBATION OF BRONCHIECTASIS SUCCESSFULLY TREATED WITH CEFTRIAXONE/SULBACTAM/DISODIUM EDETATE-1034 (ELORES™)

ABSTRACTBronchiectasis is a type of chronic obstructive pulmonary disease, defined as permanent abnormal dilation of bronchi due to vicious cycle of transmuralinfection and inflammation. Bronchiectasis is generally characterized by cough, wheeze, and dyspnea. Pathogens responsible for bronchiectasis...

Full description

Saved in:
Bibliographic Details
Published inAsian journal of pharmaceutical and clinical research Vol. 10; no. 3; p. 3
Main Author Sharma, Parag
Format Journal Article
LanguageEnglish
Published 01.03.2017
Online AccessGet full text

Cover

More Information
Summary:ABSTRACTBronchiectasis is a type of chronic obstructive pulmonary disease, defined as permanent abnormal dilation of bronchi due to vicious cycle of transmuralinfection and inflammation. Bronchiectasis is generally characterized by cough, wheeze, and dyspnea. Pathogens responsible for bronchiectasisinclude pathogens Haemophilus influenzae, Pseudomonas aeruginosa, Streptococcus pneumoniae, Staphylococcus aureus, and nontuberculousmycobacteria. Empirical antibiotic therapy and other drugs are used empirically in the management of bronchiectasis.Here, we discuss a case ofinfectious exacerbation of bronchiectasis successfully treated with an empirical use of ceftriaxone/sulbactam/disodium edetate-1034.Keywords: Bronchiectasis, Elores™, Ceftriaxone/sulbactam/disodium edetate-1034, Disodium edetate, Antibiotic resistance.
ISSN:0974-2441
0974-2441
DOI:10.22159/ajpcr.2017.v10i3.15791